Verastem, Inc. (VSTM) Form 10-Q — Nov 5, 2026
Verastem's Q3 2026 product revenue more than doubled to $24.0 million from $11.2 million a year ago, driven by growing shipments of AVMAPKI FAKZYNJA CO-PACK, which won FDA approval in May 2025 for KRAS-mutant recurrent low-grade serous ovarian cancer. Nine-month product revenue reached $67.8 million, plus a $15.0 million COPIKTRA milestone from Secura Bio brought total revenue to $82.8 million. The company still lost $74.7 million in the quarter as R&D spending surged 137% to $68.8 million, mostly to fund the rapidly expanding TARGET-D clinical program for its KRAS G12D inhibitor VS-7375. Cash stood at $172.8 million at quarter-end.
Key figures
- Revenue
- 24012000
- Total Debt
- 125000000
- Revenue Yoy
- 114%
- Total Assets
- 229637000
- Cash Position
- 172801000
- Shares Outstanding
- 126014804
- Rd expense q3 2026
- $68.8 million
- Accumulated deficit
- $1,311.0 million
- Revenue notes drawn
- $50.0 million
- Stockholders equity
- $10.1 million
- Q3 2025 product revenue
- $11.2 million
- Q3 2026 product revenue
- $24.0 million
- Initial notes outstanding
- $75.0 million
- October 2026 offering price
- $8.00 per share
- Nine month 2026 total revenue
- $82.8 million (incl. $15.0M Secura COPIKTRA milestone)
- Nine month 2026 product revenue
- $67.8 million
- October 2026 offering net proceeds
- $234.7 million
- Vs 7375 clinical trial costs q3 2026
- $25.9 million
- Revenue notes potential second tranche
- $25.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.